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Iowa Department of Public Health 
Division of Behavioral Health/Bureau of Substance Abuse  
Opioid Update: October 2020 
 
The Iowa Department of Public Health (IDPH) offers the Opioid Update to share information 
about opioid use and Iowa’s efforts to address the national opioid epidemic. Please feel free to 
submit topics to RaChel Greenwood at rachel.greenwood@idph.iowa.gov.  
 
In this issue:  
 
● Department News 
● Opioid News 




New Narcan (naloxone) Media and Marketing Campaign Launching Soon 
 
As part of the new Narcan (naloxone) initiative sponsored by the Iowa Department of 
Public Health and the Iowa Board of Pharmacy, a new awareness campaign is being 
kicked-off to remind Iowans that they can obtain a free Narcan kit at Iowa pharmacies. 
The “Reverse It” campaign, developed by ZLR 
Ignition, will consist of media and marketing 
materials that promotes the availability of 
Narcan for those that want to be better 
prepared in the event of a suspected opioid 
overdose. “We want to make sure that every 
Iowan concerned about either their own opioid 
use or the possibility of encountering someone 
experiencing a possible opioid overdose, is 
equipped with a kit and prepared to help save a 
life”, said Kevin Gabbert, Opioid Initiatives 
Director at the Iowa Department of Public 
Health.  
 
In addition to television and social media 
promotion, available materials will include 
informational cards/handouts, posters (see 
picture), stickers, table tents, and bag inserts, 
designed for pharmacies, other healthcare 
professionals, and stakeholders to utilize. 
Materials will be distributed to pharmacies in 
the coming weeks.  
 
For other healthcare professionals and stakeholders, materials will be available in mid-




In the September edition of the Opioid Update, we provided information on a shelf life 
extension program for Narcan.  The manufacturer recently issued the following 
statement correcting earlier information.  
 
Recently, you may have received a communication from Emergent BioSolutions 
regarding shelf life extension for Narcan® (naloxone HCI) Nasal Spray 4 mg. The 
following is to correct that prior communication. The FDA has approved the 
extension of the shelf life of Narcan® (naloxone HCI) Nasal Spray from 24 
months to 36 months. This extension will be applicable only to new product which 
will be labeled with the new expiration date. This product has not yet been 
distributed. Accordingly, product currently in the market which you may have in 
inventory, is still subject to the expiration dating printed on the packaging for the 
product. In other words, all Narcan Nasal Spray product remains subject to the 
expiration dating printed on its specific package. 
 
IDPH apologizes for any inconvenience this may have caused. If you have any 





Narcan must become as commonplace as CPR 
 
In this opinion piece,  Dr. Mark Calarco, the National Medical Director for Clinical 
Diagnostics for American Addiction Centers, makes the case that public availability, 
awareness and administration of Narcan should be the same as CPR. He argues that in 
light of the rising overdose deaths, a nearly 900 percent increase in calls to the disaster 
distress helpline since the pandemic began, and with research demonstrating that 
bystanders are more likely to be called upon to administer Narcan than CPR, it is time 
for a larger initiative in availability, training, and awareness of Narcan. 
 
To read this article, please click on the following link: CPR 
 
Brandeis University Launches Site to Help Communities Formulate Opioid Crisis 
Response 
 
The Opioid Policy Research Collaborative, an initiative that is part of the Institute for 
Behavioral Health at Brandeis University’s Heller School for Social Policy Management, 
has launched a new website called the Brandeis Opioid Resource Connector (BORC) to 
inform communities and local leaders on what other municipalities are doing to address 
the opioid crisis and help shape interventions of their own. 
 
“For communities and local leaders, BORC is a critical starting point and ongoing 
resource, including insights on adaptations to initiatives during the COVID-19 crisis,” 
Traci Green, director of the Opioid Policy Research Collaborative said in a news 
release. “The BORC website connects evidence to action on opioid misuse and 
overdose, which will save lives, reduce harm, and help build resilient communities.” 
 
To visit the BORC website, please click on the following link: BORC 
 
Substance use disorders linked to COVID-19 susceptibility 
 
A study recently published in the scientific journal Molecular Psychiatry, funded by the 
National Institutes of Health found that people with substance use disorders (SUDs) are 
more susceptible to COVID-19 and are more likely to experience worse outcomes than 
those without a SUD. 
 
The authors suggest that the study’s findings underscore the need to screen and then 
treat people with SUDs to help control the pandemic.  
 
To read this article about the research published in Molecular Psychiatry, please click 
here: NIH  
 
Opioid Use Linked to Hearing Loss 
 
According to a new study published in the Journal of Medical Toxicology, opioid use—
particularly heroin—has been linked with hearing loss. In a review of New Jersey Poison 
Control Center medical records from 1999 to 2018, researchers concluded that opioid-
associated otoxocity—ear poisoning—was independent of oxygen deprivation and was 
most commonly associated with heroin exposure. 
 
This research has important treatment implications, as Lawrence Weinstein, MD, 
ABHM, FASAM, FAMA, chief medical officer for American Addiction Centers, told 
Addiction Professional in an emailed statement, “Conducting a number of diagnostic 
procedures to better understand the type of hearing loss the patient presents with and 
the degree of its severity can help providers better determine the course of treatment to 
take. For example, opioid/acetaminophen combinations like Vicodin would certainly be 
avoided because acetaminophen is quite ototoxic itself. Consistent follow up with a 
patient of this nature is mandatory as is frequent communication with their 
otolaryngologist.” 
 
To read this article about the research published in the Journal of Medical Toxicology, 
please click here: NCAD 
 
To read the research article in the Journal of Medical Toxicology, please click here: 
JOURNAL 
 
Webinars and Trainings 
 
Second Annual Approaches to Pain Management Conference 
 
The Approaches to Pain Management Conference is a part of the Iowa Department of Public 
Health’s initiatives that support substance use prevention, treatment and recovery. This free 




 Identify the impacts created in the interaction between chronic pain and substance use. 
 Identify local resources in the state of Iowa for accessing resources for pain 
management. 
 Identify non-pharmaceutical approaches for managing pain. 
 
Certificates of Completion, Nursing Contact Hours and Iowa Board of Certification Continuing 
Education Units will be provided to the e-mail provided at registration. There is no fee to attend, 
but pre-registration is required. 
 
For information on registering, please click on the following link: APM2 
 
 
 
